RecruitingNot ApplicableNCT04859725

HyperSpectral Imaging in Low Grade Glioma

Validation of Label-free, Wide-field, Real-time Intra-operative Tissue Discrimination and Tumor Detection of Low Grade Glioma Using a Hyperspectral Imaging (HSI) Sensor/camera Integrated in the Operative Microscope

Sponsor

Universitaire Ziekenhuizen KU Leuven

Enrollment

10 participants

Start Date

May 31, 2021

Study Type

INTERVENTIONAL

Conditions

Low Grade Glioma of Brain

Summary

Low grade glioma (LGG) is a slowly evolving, highly invasive intrinsic brain tumor displaying only subtle tissue differences with the normal surrounding brain, hampering the attempts to visually discriminate tumor from normal brain, especially at the border interface. This makes anatomical borders hard to define during early maximal resection, which is the initial treatment strategy. Therefore, innovative, robust and easy-to-use real-time strategies for intra-operative detection and discrimination of (residual) LGG tumor tissue would strongly influence on-site, surgical decision making, enabling a maximal extent of resection. To validate this approach hyperspectral imaging (HSI) - using a SnapScan HSI-Camera (IMEC), stably mounted on an OPMI Pentero 900 microscope (Zeiss) - will be used to generate spectral imaging data patterns that discriminate in vivo low grade glioma tissue from normal brain both on the cortical and subcortical level.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a new imaging technique called hyperspectral imaging during brain surgery to help surgeons better see and identify the edges of low-grade brain tumors (gliomas), improving how much of the tumor can be safely removed. **You may be eligible if...** - You are 18 years or older - Imaging has suggested you have a low-grade glioma (a slow-growing brain tumor) that is either newly found or has returned - You are scheduled for tumor removal surgery at UZ Leuven - You can sign an informed consent form before surgery **You may NOT be eligible if...** - You are under 18 years old - Your final pathology report shows a different diagnosis than low-grade glioma Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEHyperspectral Imaging with Snapscan camera

Before, during and after the resection, HSI data ('datacubes') will be acquired by the SnapScan camera of all relevant areas of the exposed cortical surface and subcortical cavity walls. The exact points of which the datacubes will be acquired are defined by unequivocal single points on the routinely used neuronavigational system. From the points from which the datacubes have been obtained a corresponding tissue sample will be obtained (labeled biopsy) if tumor tissue is to be expected in that particular point, based on the current standard of care assessments intraoperatively using white light illumination on the microscope, intraoperative navigation and intraoperative ultrasound. As such, normally looking brain in the resection cavity wall, will only be biopsied if tumor free margins should be proven as part of the standard-of-care operative procedure (non-critically eloquent brain regions).